NCT03177460View on ClinicalTrials.gov

Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

June 7, 2017

Primary Completion Date

January 30, 2024

Study Completion Date

January 30, 2024

Conditions
Prostate AdenocarcinomaStage III Prostate Cancer AJCC v8Stage IIIA Prostate Cancer AJCC v8Stage IIIB Prostate Cancer AJCC v8Stage IIIC Prostate Cancer AJCC v8Testosterone Greater Than 150 ng/dL
Interventions
BIOLOGICAL

Daratumumab

Given IV

DRUG

FMS Inhibitor JNJ-40346527

Given PO

PROCEDURE

Radical Prostatectomy

Undergo radical prostatectomy

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT03177460 - Daratumumab or FMS Inhibitor JNJ-40346527 Before Surgery in Treating Patients With High-Risk, Resectable Localized or Locally Advanced Prostate Cancer | Biotech Hunter | Biotech Hunter